Early Psoriatic Arthritis

Rheumatic Disease Clinics of North America

Volumn 38, Issue 2, 2012, Pages 373-386

  Gladman, Dafna D ^a  

^a TORONTO WESTERN HOSPITAL   (Canada)

Author keywords

Early disease; Prognosis; Psoriasis; Psoriatic arthritis; Treatment

Indexed keywords

DISEASE MODIFYING ANTIRHEUMATIC DRUG; RHEUMATOID FACTOR; TUMOR NECROSIS FACTOR INHIBITOR;

AGE; ARTHROPATHY; CLINICAL ASSESSMENT; CLINICAL FEATURE; DIAGNOSTIC TEST; DISEASE ASSOCIATION; EARLY DIAGNOSIS; ENVIRONMENTAL FACTOR; GENDER; HEREDITY; HUMAN; IMMUNITY; PATHOGENESIS; PRIORITY JOURNAL; PSORIASIS; PSORIATIC ARTHRITIS; QUALITY OF LIFE; QUESTIONNAIRE; REVIEW; RISK FACTOR; SCREENING TEST;

ADOLESCENT; AGED, 80 AND OVER; ANTIRHEUMATIC AGENTS; ARTHRITIS, PSORIATIC; CHILD; EARLY DIAGNOSIS; FEMALE; HEALTH STATUS; HUMANS; JOINTS; MALE; QUALITY OF LIFE; SECONDARY PREVENTION; SEVERITY OF ILLNESS INDEX;

EID: 84863999439     PISSN: 0889857X     EISSN: 15583163     Source Type: Journal    
DOI: 10.1016/j.rdc.2012.05.005     Document Type: Review

References (78)

1. Taylor W.J., Gladman D.D., Helliwell P.S., et al. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum 2006, 54:2665-2673.
2. Gladman D.D. Psoriatic arthritis from Wright's era till today. J Rheumatol Suppl 2009, 83:4-8.
3. Blumberg B.S., Bunim J.J., Calkins E., et al. ARA nomenclature and classification of arthritis and rheumatism (tentative). Arthritis Rheum 1964, 7:93-97.
4. Gladman D.D., Shuckett R., Russell M.L., et al. Psoriatic arthritis - clinical and laboratory analysis of 220 patients. Q J Med 1987, 62:127-141.
5. Gorter S., van der Heijde D.M., van der L.S., et al. Psoriatic arthritis: performance of rheumatologists in daily practice. Ann Rheum Dis 2002, 61:219-224.
6. Chandran V., Raychaudhuri S.P. Geoepidemiology and environmental factors of psoriasis and psoriatic arthritis. J Autoimmun 2010, 34:J314-J321.
7. Zeng Q.Y., Chen R., Darmawan J., et al. Rheumatic diseases in China. Arthritis Res Ther 2008, 10:R17.
8. Trontzas P., Andrianakos A., Miyakis S., et al. Seronegative spondyloarthropathies in Greece: a population-based study of prevalence, clinical pattern, and management. The ESORDIG study. Clin Rheumatol 2005, 24:583-589.
9. De Angelis R., Salaffi F., Grassi W. Prevalence of spondyloarthropathies in an Italian population sample: a regional community-based study. Scand J Rheumatol 2007, 36:14-21.
10. Gelfand J.M., Gladman D.D., Mease P.J., et al. Epidemiology of psoriatic arthritis in the population of the United States. J Am Acad Dermatol 2005, 53:573-577.
11. Minaur N., Sawyers S., Parker J., et al. Rheumatic disease in an Australian Aboriginal community in North Queensland, Australia. A WHO-ILAR COPCORD survey. J Rheumatol 2004, 31:965-972.
12. Leczinsky C.G. The incidence of arthropathy in a ten-year series of psoriasis cases. Acta Derm Venereol 1948, 28:483-487.
13. Little H., Harvie J.N., Lester R.S. Psoriatic arthritis in severe psoriasis. Can Med Assoc J 1975, 112:317-319.
14. Scarpa R., Oriente P., Pucino A., et al. Psoriatic arthritis in psoriatic patients. Br J Rheumatol 1984, 23:246-250.
15. Stern R.S. The epidemiology of joint complaints in patients with psoriasis. J Rheumatol 1985, 12:315-320.
16. Barisic-Drusko V., Dobric I., Pasic A., et al. Frequency of psoriatic arthritis in general population and among the psoriatics in Department of Dermatology. Acta Derm Venereol Suppl (Stockh) 1994, 186:107-108.
17. Salvarani C., Lo Scocco G., Macchioni P., et al. Prevalence of psoriatic arthritis in Italian psoriatic patients. J Rheumatol 1995, 22:1499-1503.
18. Shbeeb M., Uramoto K.M., Gibson L.E., et al. The epidemiology of psoriatic arthritis in Olmsted County, Minnesota, USA, 1982-1991. J Rheumatol 2000, 27:1247-1250.
19. Brockbank J.E., Schentag C., Rosen C., et al. Psoriatic arthritis (PsA) is common among patients with psoriasis and family medical clinic attendees. Arthritis Rheum 2001, 44(Suppl 9):S94. [abstract].
20. Alenius G.M., Stenberg B., Stenlund H., et al. Inflammatory joint manifestations are prevalent in psoriasis: prevalence study of joint and axial involvement in psoriatic patients, and evaluation of a psoriatic and arthritic questionnaire. J Rheumatol 2002, 29:2577-2582.
21. Zachariae H. Prevalence of joint disease in patients with psoriasis: implications for therapy. Am J Clin Dermatol 2003, 4:441-447.
22. Reich K., Kruger K., Mossner R., et al. Epidemiology and clinical pattern of psoriatic arthritis in Germany: a prospective interdisciplinary epidemiological study of 1511 patients with plaque-type psoriasis. Br J Dermatol 2009, 160:1040-1047.
23. Chandran V. The genetics of psoriasis and psoriatic arthritis. Clin Rev Allergy Immunol 2012, [Epub ahead of print].
24. Chandran V., Schentag C.T., Brockbank J.E., et al. Familial aggregation of psoriatic arthritis. Ann Rheum Dis 2009, 68:664-667.
25. Karason A., Gudjonsson J.E., Upmanyu R., et al. A susceptibility gene for psoriatic arthritis maps to chromosome 16q: evidence for imprinting. Am J Hum Genet 2003, 72:125-131.
26. Liu Y., Helms C., Liao W., et al. A genome-wide association study of psoriasis and psoriatic arthritis identifies new disease loci. PLoS Genet 2008, 4:e1000041.
27. Nair R.P., Duffin K.C., Helms C., et al. Genome-wide scan reveals association of psoriasis with IL-23 and NF-kappaB pathways. Nat Genet 2009, 41:199-204.
28. Ellinghaus E., Stuart P.E., Ellinghaus D., et al. Genome-wide meta-analysis of psoriatic arthritis identifies susceptibility locus at REL. J Invest Dermatol 2012, 132:1133-1140.
29. Eder L., Chandran V., Pellet F., et al. Human leukocyte antigen risk alleles for psoriatic arthritis among psoriasis patients. Ann Rheum Dis 2012, 71:50-55.
30. Eder L., Law T., Chandran V., et al. The association between environmental factors and onset of psoriatic arthritis in patients with psoriasis. Arthritis Care Res 2011, 63:1091-1097.
31. Fitzgerald O., Winchester R. Psoriatic arthritis: from pathogenesis to therapy. Arthritis Res Ther 2009, 11:214.
32. Wright V., Moll J.M. Psoriatic arthritis. Seronegative polyarthritis 1976, 169-223. North-Holland, Amsterdam. V. Wright, J.M. Moll (Eds.).
33. Khan M., Schentag C., Gladman D. Clinical and radiological changes during psoriatic arthritis disease progression: working toward classification criteria. J Rheumatol 2003, 30:1022-1026.
34. Helliwell P., Marchesoni A., Peters M., et al. A re-evaluation of the osteoarticular manifestations of psoriasis. Br J Rheumatol 1991, 30:339-345.
35. Helliwell P.S., Hetthen J., Sokoll K., et al. Joint symmetry in early and late rheumatoid and psoriatic arthritis: comparison with a mathematical model. Arthritis Rheum 2000, 43:865-871.
36. Gladman D.D. Axial disease in psoriatic arthritis. Curr Rheumatol Rep 2007, 9:455-460.
37. Gladman D.D., Inman R., Cook R., et al. International spondyloarthritis inter-observer reliability exercise - the INSPIRE study: II. Assessment of peripheral joints, enthesitis and dactylitis. J Rheumatol 2007, 34:1740-1745.
38. Brockbank J., Stein M., Schentag C.T., et al. Dactylitis in psoriatic arthritis (PsA): a marker for disease severity?. Ann Rheum Dis 2005, 62:188-190.
39. Taylor W.J., Marchesoni A., Arreghini M., et al. A comparison of the performance characteristics of classification criteria for the diagnosis of psoriatic arthritis. Semin Arthritis Rheum 2004, 34:575-584.
40. Gladman D.D., Antoni C., Clegg D., et al. Psoriatic arthritis - epidemiology and clinical features. Ann Rheum Dis 2005, 64(Suppl 2):ii14-ii17.
41. Eder L., Chandran V., Gladman D.D. Repair of radiographic joint damage following treatment with a TNF inhibitor in psoriatic arthritis is demonstrable by three radiographic methods. J Rheumatol 2011, 38:1066-1070.
42. Wright V. Psoriatic arthritis: a comparative study of rheumatoid arthritis, psoriasis and arthritis associated with psoriasis. AMA Arch Derm 1959, 80:27-35.
43. Coulton B.L., Thomson K., Symmons D.P., et al. Outcome in patients hospitalised for psoriatic arthritis. Clin Rheumatol 1989, 2:261-265.
44. Gladman D.D. Disability and quality of life considerations. Psoriatic arthritis. Psoriasis and psoriatic arthritis: an integrated approach 2005, 118-123. Springer-Verlag, Heidelberg (Germany). G.B. Gordon, E. Ruderman (Eds.).
45. Gladman D.D. Mortality in psoriatic arthritis. Clin Exp Rheumatol 2008, 26(Suppl 5):s62-s65.
46. Rosen C.F., Mussani F., Chandran V., et al. Patients with psoriatic arthritis have worse quality of life than those with psoriasis alone. Rheumatology (Oxford) 2012, 51:571-576.
47. Kane D., Stafford L., Bresniham B., et al. A prospective, clinical and radiological study of early psoriatic arthritis: an early synovitis clinic experience. Rheumatology 2003, 42:1460-1468.
48. Gladman D.D., Thavaneswaran A., Chandran V., et al. Do patients with psoriatic arthritis who present early fare better than those presenting later in the disease?. Ann Rheum Dis 2011, 70:2152-2154.
49. Prasad R., Gladman D. Current and investigational treatment of psoriatic arthritis. Expert Opin Investig Drugs 2004, 13:139-150.
50. Mease P.J., Kivitz A.J., Burch F.X., et al. Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression. Arthritis Rheum 2004, 50:2264-2272.
51. Gladman D.D., Mease P.J., Ritchlin C.T., et al. Adalimumab for long-term treatment of psoriatic arthritis: 48-week data and subanalysis from ADEPT. Arthritis Rheum 2007, 56:476-488.
52. van der Heijde D., Kavanaugh A., Gladman D.D., et al. Infliximab inhibits progression of radiographic damage in patients with active psoriatic arthritis through one year of treatment: results from the induction and maintenance psoriatic arthritis clinical trial 2. Arthritis Rheum 2007, 66:2698-2707.
53. Kavanaugh A., van der Heijde D., McInnes I., et al. Golimumab, a human TNF-alpha antibody, administered every 4 weeks as a subcutaneous injection in psoriatic arthritis: clinical efficacy, radiographic, and safety findings through 1 year of the randomized, placebo-controlled, Go-REVEAL Study. Arthritis Rheum 2012, [Epub ahead of print].
54. Bond S.J., Farewell V.T., Schentag C.T., et al. Predictors for radiological damage in psoriatic arthritis. Results from a Single centre. Ann Rheum Dis 2007, 66:370-376.
55. Cresswell L., Chandran V., Farewell V.T., et al. Inflammation in an individual joint predicts damage to that joint in psoriatic arthritis. Ann Rheum Dis 2011, 70:305-308.
56. Chandran V., Schentag C.T., Gladman D.D. Sensitivity of the classification of psoriatic arthritis (CASPAR) criteria in early psoriatic arthritis. Arthritis Rheum 2007, 57:1560-1563.
57. D'Angelo S., Mennillo G.A., Cutro M.S., et al. Sensitivity of the classification of psoriatic arthritis criteria in early psoriatic arthritis. J Rheumatol 2009, 36:368-370.
58. Coates L., Conaghan P.G., Emery P., et al. The CASPAR criteria can be used to identify early psoriatic arthritis. Arthritis Rheum 2010, 62(Suppl 10):S916.
59. van den Berg R., van Gaalen F., van der Helm-van Mil A., et al. Performance of classification criteria for peripheral spondyloarthritis and psoriatic arthritis in the Leiden early arthritis cohort. Ann Rheum Dis 2012, [Epub ahead of print].
60. Chandran V., Schentag C.T., Gladman D.D. Sensitivity and specificity of the CASPAR criteria for psoriatic arthritis when applied to patients attending a family medicine clinic. J Rheumatol 2008, 35:2069-2070.
61. Peloso P.M., Hull P., Reeder B. The psoriasis and arthritis questionnaire (PAQ) in detection of arthritis among patients with psoriasis. Arthritis Rheum 1997, 40:S64.
62. Ibrahim G.H., Buch M.H., Lawson C., et al. Evaluation of an existing screening tool for psoriatic arthritis in people with psoriasis and the development of a new instrument: the Psoriasis Epidemiology Screening Tool (PEST) questionnaire. Clin Exp Rheumatol 2009, 27:469-474.
63. Khraishi M., Mong J., Mugford G., et al. The electronic Psoriasis and Arthritis Screening Questionnaire (ePASQ): a sensitive and specific tool to diagnose psoriatic arthritis patients. J Cutan Med Surg 2011, 15:143-149.
64. Husni M.E., Meyer K.H., Cohen D.S., et al. The PASE questionnaire: pilot-testing a psoriatic arthritis screening and evaluation tool. J Am Acad Dermatol 2007, 57:581-587.
65. Dominguez P.L., Husni M.E., Holt E.W., et al. Validity, reliability, and sensitivity-to-change properties of the psoriatic arthritis screening and evaluation questionnaire. Arch Dermatol Res 2009, 301:573-579.
66. Gladman D.D., Schentag C.T., Tom B.D., et al. Development and initial validation of a screening questionnaire for psoriatic arthritis: the Toronto Psoriatic Arthritis Screen (ToPAS). Ann Rheum Dis 2009, 68:497-501.
67. Diaconu-Popa D.A., Driessen R.J.B., Kerkhof P.C.M., et al. Performance of two screening instruments, ToPAS and PASE, for detecting psoriatic arthritis in patients with psoriasis. Ann Rheum Dis 2009, 68(Suppl 3):656.
68. Wilson F.C., Icen M., Crowson C.S., et al. Incidence and clinical predictors of psoriatic arthritis in patients with psoriasis: a population-based study. Arthritis Rheum 2009, 61:233-239. [Erratum appears in Arthritis Rheum 2010;62:574].
69. Chandran V., Cook R.J., Edwin J., et al. Soluble biomarkers differentiate patients with psoriatic arthritis from those with psoriasis without arthritis. Rheumatology (Oxford) 2010, 49:1399-1405.
70. Bonifati C., Elia F., Francesconi F., et al. The diagnosis of early psoriatic arthritis in an outpatient dermatological centre for psoriasis. J Eur Acad Dermatol Venereol 2012, 26:627-633.
71. Gisondi P., Tinazzi I., Del G.M., et al. The diagnostic and therapeutic challenge of early psoriatic arthritis. Dermatology 2010, 221(Suppl 1):6-14.
72. Anandarajah A.P., Ritchlin C.T. The diagnosis and treatment of early psoriatic arthritis. Nat Rev Rheumatol 2009, 5:634-641.
73. Svensson B., Holmstrom G., Lindqvist U. Development and early experiences of a Swedish psoriatic arthritis register. Scand J Rheumatol 2002, 31:221-225.
74. Lindqvist U.R., Alenius G.M., Husmark T., et al. The Swedish early psoriatic arthritis register - 2-year followup: a comparison with early rheumatoid arthritis. J Rheumatol 2008, 35:668-673.
75. Gladman D.D., Ng Tung Hing E., Schentag C.T., et al. Remission in psoriatic arthritis. J Rheumatol 2001, 28:1045-1048.
76. Gladman D.D., Farewell V.T., Husted J., et al. Mortality studies in psoriatic arthritis. Results from a single centre. II. Prognostic indicators for mortality. Arthritis Rheum 1998, 41:1103-1110.
77. Chandran V., Schentag C.T., Gladman D.D. Reappraisal of the effectiveness of methotrexate in psoriatic arthritis: results from a longitudinal observational cohort. J Rheumatol 2008, 35:469-471.
78. Abu-Shakra M., Gladman D.D., Thorne J.C., et al. Longterm methotrexate therapy in psoriatic arthritis: clinical and radiologic outcome. J Rheumatol 1995, 22:241-245.